It’ll be a busy December for dividend growth investors, with 25 companies announcing their annual increases. Check out the ...

One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent ...

Pfizer (NYSE:PFE) discovers, develops, manufactures, markets, distributes and sells biopharmaceutical products in the United ...

Pfizer's high initial dividend yield, solid ratings, and promising pipeline make it a potentially undervalued investment. See ...

Stocks knocked down in the first ten months of the year often suffer further damage as people sell for tax losses. But they ...

Padcev, a drug Pfizer acquired in 2023, is a part of the only chemo-free treatment for bladder cancer patients newly ...

Plans to build 112 homes on land once occupied by Pfizer have been approved - but none of the properties will be classed as ...

Despite Pfizer 's ( PFE 1.47%) recent struggles with falling earnings and a bid by an activist investor to unseat its ...

Pfizer Inc. (NYSE: PFE), and AstraZeneca plc (NASDAQ: AZN) may have faded from the spotlight since the peak of the COVID-19 ...

Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...

Pfizer may not be able to recover the $75.2 million that was left from a Securities and Exchange Commission insider trading ...

On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...